Is AstraZeneca a Dividend Stock to Watch?

Shares of pharma giant AstraZeneca (NYSE: AZN  ) rose slightly today -- despite reporting mediocre third quarter earnings. Year-over-year revenue dropped, and sales took a hit after some of the company's high profile drugs lost patent protection this year.

In the following video, health care analysts Max Macaluso and David Williamson discuss these results, AstraZeneca's new CEO, and one of AstraZeneca's potential acquisition targets -- Amarin  (Nasdaq: AMRN  ) .

 

The biotech space can make or break investors overnight, and while Amarin might not disappear into thin air,  the success of its new triglyceride lowering drug is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with our new premium research report. Click here now to keep reading.

 


Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2077982, ~/Articles/ArticleHandler.aspx, 4/21/2014 1:26:46 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement